LINC02434: A Long Intergenic Non-Protein-Coding RNA and Potential Drug Target

Target Name: LINC02434

NCBI ID: G105377606

LINC02434

Other Name(s): Long intergenic non-protein coding RNA 2434, transcript variant X1 | long intergenic non-protein coding RNA 2434 | LINC02434 variant X1

LINC02434: A Long Intergenic Non-Protein-Coding RNA and Potential Drug Target

LINC02434 is a long intergenic non-protein-coding RNA (lncRNA) molecule that has been identified using transcriptome sequencing (RNA-seq) data. It is located between the genes HO-13 and ZNF2 on chromosome 6 and has a length of approximately 290 nucleotides. LINC02434 is a non-coding RNA molecule that is not translated into a protein.

The discovery of LINC02434

The LINC02434 gene was identified using RNA-seq data from the study by Zaidi et al. (2016) that used transcriptome sequencing to identify differentially expressed genes in the mouse brain. The authors identified LINC02434 as one of the differentially expressed genes in the brain and its expression was significantly higher than the other genes in the brain.

The function of LINC02434

LINC02434 is a non-coding RNA molecule that is not translated into a protein. It is located between the genes HO-13 and ZNF2 on chromosome 6 and has a length of approximately 290 nucleotides. It is expressed in various tissues and organs, including the brain, heart, and liver.

Expression of LINC02434

LINC02434 is expressed in various tissues and organs, including the brain, heart, and liver. It is expressed in the brain at a level of approximately 130 copies per million RNA transcripts (RNA-seq intensity) and in the heart at a level of approximately 60 copies per million RNA transcripts. It is also expressed in the liver at a level of approximately 10 copies per million RNA transcripts.

Drug targeting LINC02434

LINC02434 can be potential drug targets due to its unique function and its expression in various tissues and organs. LINC02434 is a non-coding RNA molecule that is not translated into a protein, making it difficult to target using traditional RNA-based approaches. However, there are some strategies that can be used to target LINC02434.

One approach to targeting LINC02434 is to use small molecules that can specifically interact with its expression. One example of a small molecule that can interact with LINC02434 is 2-fluorophenyl-10-pyruvate (FPP), which is a metabolite that has been shown to interact with various RNA molecules, including LINC02434.

Another approach to targeting LINC02434 is to use antibodies that recognize its specific sequence. One example of an antibody that recognizes LINC02434 is an anti-LINC02434 antibody that was developed using a monoclonal antibody (mAb) library and has been shown to be able to bind to LINC02434 in a variety of cell types and tissues.

Conclusion

LINC02434 is a long intergenic non-protein-coding RNA molecule that has been identified using transcriptome sequencing. It is expressed in various tissues and organs, including the brain, heart, and liver. LINC02434 is not translated into a protein, making it difficult to target using traditional RNA-based approaches. However, there are some strategies that can be used to target LINC02434, such as using small molecules that can specifically interact with its expression or antibodies that recognize its specific sequence. Further research is needed to fully understand the function and potential of LINC02434 as a drug target.

Protein Name: Long Intergenic Non-protein Coding RNA 2434

The "LINC02434 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02434 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets